{"id":"experimental-cyclic-regimen","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not fully understood, but it is believed to involve a complex interplay of molecular interactions that ultimately lead to the desired therapeutic effect.","oneSentence":"Experimental Cyclic Regimen works by targeting a specific molecular pathway to modulate cellular behavior.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:29:58.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT07492225","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-08-15","conditions":"Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma","enrollment":120},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT06745908","phase":"PHASE3","title":"ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-01","conditions":"NSCLC Stage IV","enrollment":460},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT06780098","phase":"PHASE2","title":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-28","conditions":"Lung Neoplasm","enrollment":144},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT07463313","phase":"PHASE2, PHASE3","title":"6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03","conditions":"Thymoma and Thymic Carcinoma","enrollment":116},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT05597878","phase":"PHASE2, PHASE3","title":"Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy","status":"SUSPENDED","sponsor":"Wake Forest University Health Sciences","startDate":"2023-04-18","conditions":"Pain Management, Opioid Use, Prostate Cancer","enrollment":100},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT07452978","phase":"PHASE2","title":"Propranolol for Early Secondary Prevention of Post-Traumatic Stress Disorder in Women Victims of Sexual Violence","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2026-09-01","conditions":"PTSD - Post Traumatic Stress Disorder","enrollment":34},{"nctId":"NCT02659293","phase":"PHASE3","title":"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2016-04-26","conditions":"Multiple Myeloma","enrollment":180},{"nctId":"NCT07438106","phase":"PHASE2","title":"A Phase III Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02","conditions":"Locally Advanced Pancreatic Cancer With KRAS G12D Mutation","enrollment":30},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT07425795","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-10","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":36},{"nctId":"NCT07422506","phase":"NA","title":"A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion","status":"RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-01-01","conditions":"Missed Abortion, Early Pregnancy Failure","enrollment":580},{"nctId":"NCT05017545","phase":"PHASE1, PHASE2","title":"Carfilzomib and Belatacept for Desensitization","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-28","conditions":"Highly Sensitized Prospective Kidney Transplant Recipients","enrollment":21},{"nctId":"NCT06731907","phase":"PHASE2","title":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-30","conditions":"Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT07264114","phase":"NA","title":"Aquatic High-Intensity Interval Training for Parkinson's Disease","status":"RECRUITING","sponsor":"Pardis Specialized Wellness Institute","startDate":"2025-12-10","conditions":"Parkinson Disease","enrollment":56},{"nctId":"NCT03388190","phase":"PHASE2","title":"METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin","status":"COMPLETED","sponsor":"University Hospital, Akershus","startDate":"2018-05-29","conditions":"Colorectal Cancer Metastatic","enrollment":80},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT07401784","phase":"NA","title":"Efficacy and Safety Evaluation of Remote Ischemic Adaptation ( Intermittent Pressure Stimulation ) in the Treatment of Insomnia After Stroke","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2026-01-27","conditions":"Cerebral Apoplexy, Depression Anxiety Disorder, Cerebrovascular Disease","enrollment":40},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT01358747","phase":"PHASE3","title":"Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-05","conditions":"Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT04419649","phase":"PHASE2","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Takeda","startDate":"2020-08-19","conditions":"Myelodysplastic Syndromes, Cytopenia","enrollment":160},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT05331521","phase":"PHASE3","title":"A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).","status":"RECRUITING","sponsor":"University Hospital Heidelberg","startDate":"2021-04-07","conditions":"Oligodendroglioma","enrollment":406},{"nctId":"NCT04495088","phase":"PHASE3","title":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ralf Hofheinz","startDate":"2020-09-30","conditions":"Rectal Cancer","enrollment":550},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT07381972","phase":"PHASE3","title":"Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-11-24","conditions":"Nodular Basal Cell Carcinoma of Skin","enrollment":142},{"nctId":"NCT07380646","phase":"PHASE2","title":"the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Leucogen, Ribociclib, Neutropenia (Low White Blood Cell Count)","enrollment":94},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT07284134","phase":"PHASE3","title":"JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-12-24","conditions":"Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":560},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT07005570","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）","status":"RECRUITING","sponsor":"Dechang Diao","startDate":"2025-05-01","conditions":"pMMR/MSS Locally Advanced Rectal Cancer","enrollment":86},{"nctId":"NCT06930794","phase":"PHASE3","title":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","status":"RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2025-07-07","conditions":"Non-Small Cell Lung Cancer","enrollment":300},{"nctId":"NCT07347340","phase":"PHASE3","title":"Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Diminished Ovarian Reserve (DOR)","enrollment":348},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340489","phase":"PHASE2","title":"Serplulimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-03","conditions":"Cervical Cancer","enrollment":216},{"nctId":"NCT07336953","phase":"PHASE3","title":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":198},{"nctId":"NCT06312982","phase":"PHASE2, PHASE3","title":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-03-16","conditions":"Locally Advanced Rectal Carcinoma","enrollment":375},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT05327894","phase":"PHASE3","title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2022-12-15","conditions":"Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":160},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT05504252","phase":"PHASE2","title":"METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2022-10-05","conditions":"Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma","enrollment":80},{"nctId":"NCT07319364","phase":"PHASE1","title":"A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Fecal Microbiota Transplantation (FMT), Gastrointestinal Neoplasms, Antineoplastic Agents","enrollment":90},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT04959500","phase":"PHASE2","title":"Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-07-21","conditions":"Glioblastoma","enrollment":150},{"nctId":"NCT07304388","phase":"PHASE2","title":"HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-10","conditions":"Intrahepatic Cholangiocarcinoma (Icc)","enrollment":96},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT07299149","phase":"PHASE2","title":"Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-25","conditions":"Follicular Lymphoma","enrollment":34},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07192068","phase":"PHASE2","title":"Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-10-30","conditions":"Non-Small Cell Lung Cancer, Sarcoma, Head &Amp; Neck Cancer","enrollment":105},{"nctId":"NCT07213557","phase":"PHASE2","title":"Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12","conditions":"Advanced or Metastatic Gastrooesophageal Carcinoma","enrollment":84},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT07272291","phase":"PHASE2","title":"A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-25","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":48},{"nctId":"NCT07270939","phase":"NA","title":"Optimizing Enteral Nutrition Regimen for Critically Ill Patients","status":"NOT_YET_RECRUITING","sponsor":"Hamad Medical Corporation","startDate":"2025-12-30","conditions":"Critical Illness, Enteral Nutrition, Ventilator Associated Pneumonia","enrollment":150},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT06476184","phase":"PHASE3","title":"Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2024-07-30","conditions":"Ovarian Cancer","enrollment":250},{"nctId":"NCT06402864","phase":"PHASE3","title":"Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2024-03-26","conditions":"Adult With Intermediate Low or Mid Rectal Adenocarcinoma","enrollment":212},{"nctId":"NCT06920251","phase":"PHASE2","title":"Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-09-11","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":40},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07257380","phase":"PHASE2","title":"Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-30","conditions":"Gastric / Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":43},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT07239466","phase":"PHASE2","title":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-01","conditions":"Rectal Cancer, Radiotherapy, Immunotherapy","enrollment":48},{"nctId":"NCT07240194","phase":"PHASE2","title":"The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Large B-cell Lymphoma, TP53","enrollment":24},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT03997435","phase":"PHASE2","title":"FOLFOXIRI With or Without Intensification for Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2019-09-10","conditions":"Rectal Cancer","enrollment":72},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT01592370","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-08-02","conditions":"Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma","enrollment":320},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT04644289","phase":"PHASE2","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","status":"RECRUITING","sponsor":"AGO Research GmbH","startDate":"2022-05-05","conditions":"Epithelial Ovarian Cancer","enrollment":60},{"nctId":"NCT04776655","phase":"PHASE3","title":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2021-04-30","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer, RAS Mutation","enrollment":280},{"nctId":"NCT06933524","phase":"PHASE1","title":"Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Autotelicbio","startDate":"2025-12-01","conditions":"Solid Tumors","enrollment":24},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT07187505","phase":"NA","title":"Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-07-01","conditions":"Acute Promyelocytic Leukemia (APL)","enrollment":28},{"nctId":"NCT07175636","phase":"PHASE2","title":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer","enrollment":66},{"nctId":"NCT04851613","phase":"PHASE3","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Laekna Limited","startDate":"2022-02-18","conditions":"Breast Cancer","enrollment":256},{"nctId":"NCT07172685","phase":"NA","title":"Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-07-30","conditions":"Prostate Cancer","enrollment":116},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["three separate 6 month cycles of daily Forteo, each followed by one of Prolia"],"phase":"marketed","status":"active","brandName":"Experimental Cyclic Regimen","genericName":"Experimental Cyclic Regimen","companyName":"Health Research, Inc.","companyId":"health-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Experimental Cyclic Regimen works by targeting a specific molecular pathway to modulate cellular behavior. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}